Pioneering placental mesenchymal stem cell and exosome therapies — backed by FDA investigational new drug (IND) authorization and global patent protection.
16+
Preclinical Studies
US FDA
IND Authorization
2006
Research Since
29+
Patents Applied
FDA IND
Approved Clinical
Research
What We Do
Transforming Regenerative Medicine
"If the 20th century was the era of drug therapy, the 21st century will be the era of cell therapy." — George Daley, Dean, Harvard Medical School
🧬
Placental Stem Cells
Proprietary isolation of placental mesenchymal stem cells (pcMSC) with superior immunomodulatory and regenerative capabilities — non-invasively sourced and age-independent.
🔬
X-Exosome Technology
World-first functional exosome platform with Japanese patent secured and US patent pending. Nano-scale vesicles capable of crossing the blood-brain barrier for CNS applications.
💊
HPSC Cell Therapy Platform
Registered cell therapy product under FDA IND approval — one of only two globally authorized placental cell drug programs. Now in human clinical study stages.
Scientific Edge
Why Placental Stem Cells?
Most global cell therapy programs rely on umbilical cord or adipose-derived stem cells. Placental mesenchymal stem cells are far more potent — but vastly more difficult to isolate and standardize.
We solved both challenges. Our proprietary single-cell purification and serum-free culture technology produces pharmaceutical-grade placental stem cells at scale.
Non-tumorigenic verified — proven safe for clinical use
Quantifiable, scalable GMP-grade production
pcMSC vs Other MSC Sources — Differentiation Potential
pcMSC (Placental)
Superior ★
UC-MSC (Umbilical)
Good
ADSC (Adipose)
Moderate
BMSC (Bone Marrow)
Moderate
Key Advantages of pcMSC
25th
Sub-generations
0%
Tumorigenic
GMP
Grade Certified
Milestones
Our Journey
2006
HPSC+ Program Founded
Launched the Human Pluripotent Stem Cell research program with collaboration from National Taiwan University, Taipei Medical University, and Academia Sinica.
2013
Nobel Prize Validation
James E. Rothman received the Nobel Prize in Physiology or Medicine for discoveries related to cellular vesicle transport — foundational to exosome science.
2022
Compassionate Use Success & Science Publication
HPSC demonstrated significant therapeutic effects in compassionate use cases. Published in Frontiers in Immunology. Clinical trial registered: NCT05886985.
2023
FDA IND Authorization
Received US FDA Investigational New Drug approval — one of only two placental cell therapy programs globally to achieve this milestone. Entered human clinical stage.
2024
Japan Exosome Patent Granted
World's first functional exosome therapy patent secured in Japan. US patent application in progress. Asia-Pacific Bioprocessing Excellence Award received.
2025
Biospring X (M) Sdn Bhd Incorporated · 2026 Expansion
Malaysian entity (Reg. 202501004960) established in Kuala Lumpur in February 2025, expanding our presence in Southeast Asia under the HPSC BioSeed brand. Further regional growth planned for 2026.
Global Collaboration
Research Partners
We collaborate with internationally recognized academic and medical institutions across Asia and North America.
🎓 University of California, Davis (UC Davis)
🎓 National Taiwan University
🎓 Taipei Medical University
🎓 Academia Sinica
🏭 Industrial Technology Research Institute
🌐 800+ Participating Institutions
👨🔬 130+ Specialists Network
About HPSC BioSeed
A World-Class Biotech Built on Decades of Science
HPSC BioSeed is a biotechnology company dedicated to the research, development, and commercialization of placental stem cell and exosome-based regenerative therapies. Our mission: advance next-generation cell therapies capable of addressing complex diseases through immune modulation, tissue regeneration, and precision cellular medicine.
🏭
TWD 2 Billion Investment
Fully automated stem cell culture systems with real-time monitoring, sterile environment culture technology, and automated media replacement — meeting international GMP standards.
🌏
Southeast Asia Expansion
Biospring X (M) Sdn. Bhd. incorporated in Malaysia in February 2025 (Reg. No. 202501004960), bringing cutting-edge cell therapy to the ASEAN market.
📊
800+ Institution Network
Our research network spans over 800 participating institutions and 130+ specialists in stem cell biology, clinical research, biotechnology manufacturing, and medical management.
"If the 20th century was the era of drug therapy, the 21st century will be the era of cell therapy."
George Daley — Dean, Harvard Medical School · Director, Stem Cell Transplantation Program, Boston Children's Hospital · President, ISSCR (2007–2008)
Our Platform
Comprehensive Research Infrastructure
Our research and development center integrates the most advanced bioprocessing technologies:
Fully automated stem cell culture systems
Real-time monitoring of cell growth conditions
Sterile environment culture technology
Automated media replacement systems
Biosafety cabinets and CO₂ incubators
Central control center and cell processing rooms
Our quality and compliance framework:
Good Manufacturing Practices (GMP)
Good Tissue Practice (GTP)
Serum-Free Medium (SFM) culture systems
Master Cell Bank (MCB) management
Chemistry, Manufacturing & Controls (CMC)
Institutional Review Board (IRB) oversight
Facility Overview — 2026
Investment & Capacity at a Glance
Facility Investment Breakdown (TWD million)
Cell Culture Systems
850M
QC & QA Labs
600M
R&D Equipment
450M
Infrastructure
250M
Network Scale (2026)
800+
Institutions
130+
Specialists
29+
Patents
Taiwan Operations
Core HQ
Malaysia (2025)
Established
ASEAN Expansion
2026 Target
Science & Technology
Two Platforms. One Vision.
We have built two complementary proprietary technology platforms — placental stem cell therapy and functional exosome technology — to address the most challenging unmet medical needs.
Platform 01
Stem Cell Technology Platform
Stem cells possess two fundamental biological characteristics discovered in 1961 by Ernest A. McCulloch and James Till at the University of Toronto — self-renewal and differentiation. These make them the cornerstone of regenerative medicine.
The human body contains approximately 37 trillion cells. As we age, stem cell numbers and activity decline — a process linked to degenerative diseases, reduced tissue repair, and chronic illness. HPSC BioSeed's research targets this decline with placental-derived therapeutics.
Ability to become specialized cell types — bone, cartilage, nerve, immune, and more.
Stem Cell Potency Classification
Totipotent
Highest
Pluripotent
Very High
Multipotent (pcMSC)
High ★
Oligopotent
Limited
Unipotent
Single
★ Our pcMSC sits in the Multipotent tier — clinically the optimal balance of versatility, safety, and scalability for therapeutic use.
Comparative Analysis
Why Placental MSCs Outperform Other Sources
Stem Cell Type
Source
Harvesting
Age Effect
Potency
BMSC (Bone Marrow)
Bone marrow
Invasive
Significant decline
Moderate
ADSC (Adipose)
Adipose tissue
Invasive
Significant decline
Moderate
UC-MSC (Umbilical Cord)
Umbilical cord
Non-invasive
Minimal
Good
HPSC pcMSC (Placental)
Placental tissue
Non-invasive
Minimal
Superior ★
MSC Source — Differentiation Lineage Comparison
Tissue Source
Adipocyte
Chondrocyte
Osteocyte
Cardiomyocyte
Neural
Endothelial
Bone Marrow (BMSC)
✓
✓
✓
—
—
—
Adipose (ADSC)
✓
✓
✓
—
—
—
Umbilical Cord (UCMSC)
✓
✓
✓
✓
—
—
Placental (HPSC pcMSC)
✓
✓
✓
✓
✓
✓
Source: Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell. Mol. Life Sci. 77, 2771–2794 (2020).
Proprietary IP
Our Core Technologies
Six breakthrough innovations that make pharmaceutical-grade placental stem cell therapy possible — innovations that no other company has combined.
🛡️
Non-Tumorigenic Verification
Proprietary technology proving our stem cells will not promote cancer — a critical safety requirement for any cell therapy drug application. Backed by fluorescent tracking studies.
🧪
Single-Cell Purification
Unique single-cell isolation and expansion technology enabling pharmaceutical standardization from complex mixed placental cell populations. Patented in Taiwan.
🌿
Serum-Free Culture Medium
Proprietary patented serum-free, xenobiotic-free culture medium — eliminating fetal bovine serum (FBS) risks for safer, more consistent, GMP-compliant cell production.
📈
25-Subgeneration Technology
Proprietary formula extends cell viability to 25 sub-generations — far beyond the normal 5–8 cycles — while maintaining full biological potency and genomic stability.
📋
Extensive Research Datasets
16+ preclinical studies with comprehensive safety, efficacy, and mechanism-of-action data supporting the IND application and ongoing clinical trials.
⚡
Dual-Function Stem Cells
Our pcMSCs demonstrate both regenerative AND immunomodulatory capabilities — a combination not found in other MSC types, dramatically expanding therapeutic applications.
Platform 02
X-Exosome Technology Platform
Exosomes are nano-scale extracellular vesicles (30–150 nm) secreted by cells, carrying proteins, RNA, and lipids as intercellular messengers. In 2013, James E. Rothman received the Nobel Prize in Physiology or Medicine for discoveries related to cellular vesicle transport mechanisms — validating the scientific foundation of exosome therapy.
Our proprietary X-Exosome platform focuses on functional exosome therapeutics derived from our placental stem cells — combining the biological potency of stem cells with the delivery advantages of nano-scale vesicles.
World's first functional exosome patent — Japan (granted)
US functional exosome patent — pending
Capable of crossing the blood–brain barrier
High biological activity and efficient tissue penetration
Applications in drug delivery, disease diagnosis, tissue regeneration
BREAKING
X.Exosome is about to receive its US patent — building on our world-first Japan functional exosome patent. Not just first, but only.
01
Process Patent
02
Proven Non-Cancer-Promoting
03
Single Purification Technology
04
Serum-Free Culture Patent
05
Full Germ Layer Function
06
Award-Winning Culture Process
07
USFDA / IND Approval
08
US Stem Cell Therapy Patent
09
Japan Exosome Therapy Patent
10
Successful Compassionate Use
11
Powerful Dual-Effect Function
12
Mass Production at Standard
HPSC 12-STAR RATING SYSTEM
Clinical Applications
Addressing Unmet Medical Needs
Many conditions still lack effective treatments. Our platform targets diseases where conventional medicine has failed — or where delivery mechanisms are inadequate.
Alzheimer's Disease
ALS
Acute Lung Injury / ARDS
Pulmonary Fibrosis
Parkinson's Disease
Multiple Sclerosis
Rheumatoid Arthritis
Osteoarthritis
Myocardial Infarction
Ischemic Stroke
Diabetes & Diabetic Foot
Crohn's Disease / IBD
Product Pipeline
HPSC Cell Therapy Platform
Our proprietary HPSC platform is a comprehensive system combining placental stem cell therapy and exosome technology for advanced regenerative medicine — backed by FDA IND authorization.
Product Line 01
HPSC®
Placenta-Derived Maternal Stem Cell Therapy
pcMSC derived from the choriodecidual membrane of the placenta (maternal origin). Exhibits powerful immune modulation and angiogenesis stimulation, making it particularly suited for inflammatory and vascular conditions.
Immune ModulationAngiogenesisAnti-InflammatoryFDA IND ✓
Product Line 02
HPSC®-b
Placenta-Derived Fetal Stem Cell Therapy
pcMSC derived from the fetal side of the placenta — characterized by high tissue regeneration and cellular repair potential, with strong differentiation capacity into multiple tissue types.
Functional exosomes derived from our proprietary pcMSC cultures. Features high biological activity, efficient tissue penetration, and the unique ability to cross the blood–brain barrier — enabling CNS applications.
The US FDA has approved our IND application — confirming the scientific validity and clinical potential of our placental stem cell research. This is among the most significant regulatory milestones in cell therapy development.
Of all global cell therapy IND applications, placental cell therapy programs are exceedingly rare. Only two organizations worldwide have received FDA authorization for placental cell-based drug development:
HPSC BioSeed — Commercial cell therapy program
UC Davis — Academic research program (future collaboration partner)
CLINICAL TRIAL: NCT05886985
✓ IND Approved
US FDA authorization received — entered human clinical study stages
✓ 16+ Preclinical Studies
Comprehensive preclinical safety and efficacy data package completed
✓ Published Research
Frontiers in Immunology publication — compassionate use clinical outcomes (2022)
✓ Yahoo Finance Listed
Parent company publicly accessible: VSBC on Yahoo Finance
Development Stage Overview
Proposed Clinical Indications — 2025–2026
Pipeline Progress by Indication Category
ALI / ARDS (Primary)
Phase I/II Clinical
Cardiovascular
Preclinical Complete
Autoimmune
Preclinical Complete
Neurological
IND Preparation
Metabolic / Diabetes
IND Preparation
Musculoskeletal
Research Stage
Reproductive System
Research Stage
Clinical Evidence
Preclinical Study: Acute Lung Injury (ALI/ARDS)
Animal studies investigated the therapeutic effects of HPSC pcMSC in an acute lung injury (ALI) mouse model — a preclinical model relevant to ARDS and severe COVID-19 complications.
Results demonstrated significant therapeutic benefit across all measured parameters.
Significant reduction in inflammatory cell counts in bronchoalveolar lavage
Marked improvement in lung tissue condition (HE staining confirmed)
Enhanced survival outcomes vs. untreated control groups
Statistically significant improvement in all parameters (p < 0.05)
Publication
Frontiers in Immunology (2022) · NCT05886985
COVID-19 Compassionate Use — Immune Marker Improvement
CRP Reduction
−78%
IL-6 Reduction
−65%
LDH Reduction
−55%
Survival (28-day)
100% (5/5)
Source: Frontiers in Immunology, 2022. n=5 severe COVID-19 patients refractory to standard treatment.
Research Overview
The Science Behind Our Therapies
From the first discovery of stem cells in 1961 to our FDA IND approval — decades of foundational science support our approach to regenerative medicine.
"Stem cells represent a revolutionary frontier in regenerative medicine and hold the potential to transform the future of healthcare."
— HPSC BioSeed Research Mission
Scientific Foundation
Key Scientific Milestones
1961
Discovery of Stem Cells
Ernest A. McCulloch and James Till at the University of Toronto identify stem cells in bone marrow — establishing the two defining characteristics: self-renewal and differentiation.
1996
Dolly the Sheep — Cellular Reprogramming Demonstrated
Prof. Ian Wilmut's team clones the first mammal from an adult somatic cell, proving that mature cell nuclei can be reprogrammed — a foundational concept for stem cell therapy.
1998
First Human Embryonic Stem Cells Isolated
Dr. James Thomson at University of Wisconsin isolates and cultures the first human embryonic stem cell lines — named "Science of the Year" in 2000.
2006
HPSC+ Program Launched
Our Human Pluripotent Stem Cell research program begins with collaborations across National Taiwan University, Taipei Medical University, Academia Sinica, and ITRI.
2013
Nobel Prize for Vesicle Transport
James E. Rothman, Randy Schekman, and Thomas C. Südhof receive the Nobel Prize in Physiology or Medicine — validating the scientific basis for exosome therapy.
Classification
Stem Cell Classification
Totipotent
Capable of generating a complete organism. Most potent — found only in early embryonic stages (days 1–8 post-fertilization).
Pluripotent
Can differentiate into nearly all cell types of the three germ layers. Foundation of embryonic stem cell research (ESC / iPSC).
Multipotent ★
Can become multiple related cell types within a lineage. Our HPSC pcMSC falls here — the clinically optimal tier for safe and scalable therapy.
Unipotent
Can produce only one specific cell type. Most restricted — but important for targeted tissue renewal.
Mechanism of Action
How pcMSC Therapy Works
pcMSC Therapeutic Mechanisms
Paracrine Signalling
Primary
Immune Modulation
Primary
Mitochondria Transfer
Active
Extracellular Vesicles
Active
Direct Differentiation
Supporting
Based on: J Biomed Sci 2021;28(1):28 — HPSC BioSeed parent company publication.
Our research network spans leading academic institutions and research centers across North America and Asia. These partnerships drive scientific validation, technology development, and clinical translation of our therapies.
UC Davis (Future Clinical Partner)
National Taiwan University
Taipei Medical University
Academia Sinica
Industrial Technology Research Institute
800+
Participating Institutions
130+
Domain Specialists
16+
Preclinical Studies Completed
Recognition & IP
Awards, Patents & Certifications
Our intellectual property portfolio and award recognition reflect years of pioneering research — and our standing as a global leader in placental stem cell biotechnology.
🏛️
Taiwan Patents
Multiple patents including process patents, practical new model patents, and cell therapy patents registered and certified in Taiwan.
🇯🇵
Japan Exosome Patent
World's first and only functional exosome therapy patent granted in Japan — establishing global IP leadership in exosome-based medicine.
🇺🇸
US Patents
Stem cell therapy patent granted in the US. Functional exosome US patent pending — expected to be the world's first in this category.
Global Patent Distribution (29 Applied · 17 Granted · As of 2026)
Taiwan (TW)
9 Granted
China (CN)
5 Granted
Japan (JP)
2 Granted
United States (US)
1 Granted
Germany (DE)
1 Granted
PCT (International)
Pending
EU (EP)
Pending
Singapore (SG)
Pending
Korea (KR)
Pending
More patents ready to be applied in 2026. For biomedical companies, technology patents are core value.
Certificate Gallery
Official Certifications & Awards
Certificate of Patent — Taiwan
Practical New Model Patent Certificate
18th National Innovation Award
16th National Innovation Award
Certificate of Patent — Japan (Exosome)
National Innovation Award
Asia-Pacific Bioprocessing Excellence Awards
Research Recognition Certificate
Global Patent Distribution
Key Recognitions
🏆
18th Taiwan National Innovation Award
Recognized for breakthrough innovation in stem cell biotechnology — one of Taiwan's most prestigious scientific achievement honors.
🏆
16th Taiwan National Innovation Award
Earlier recognition for foundational stem cell research contributions — demonstrating sustained innovation across multiple program cycles.
🌏
Asia-Pacific Bioprocessing Excellence Awards 2023
Regional recognition for high-quality clinical-grade bioprocessing technology — validating our manufacturing standards at an international level.
🔬
ISCT Conference Presentation
International Society for Cell & Gene Therapy — presenting research on HPSC pcMSC therapeutic effects in acute respiratory failure (Cytotherapy, Vol 26, June 2024).
Get in Touch
Connect With HPSC BioSeed
Whether you are a researcher, investor, medical professional, or potential partner — we welcome inquiries about our science, pipeline, and collaboration opportunities.
Malaysia Office
🏢
Biospring X (M) Sdn. Bhd.
Kuala Lumpur, Malaysia
Reg. No. 202501004960 (1606374-P)
🌐
Website
hpsc.com.my
📋
Incorporated
February 4, 2025 · Companies Act 2016 (ACT 777)
🗓️
Current Year
2026 — Regional expansion in progress across Southeast Asia
Enquiry Areas
🔬 Research Collaboration
Academic institutions and research organizations interested in joint studies or data sharing.
💼 Investor Relations
Investment inquiries — parent company VSBC listed on Yahoo Finance for public reference.
🏥 Clinical Partnerships
Medical institutions and clinicians interested in our FDA-authorized clinical programs.
🌏 Distribution & Licensing
Southeast Asia market expansion and technology licensing opportunities.
Follow Our Science
Read our published clinical data and track our FDA clinical trial progress.
